|
1
|
Carlin BI and Andriole GL: The natural
history, skeletal complications, and management of bone metastases
in patients with prostate carcinoma. Cancer. 88:2989–2994. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vousden KH and Prives C: Blinded by the
light: the growing complexity of p53. Cell. 137:413–431. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goh AM, Coffill CR and Lane DP: The role
of mutant p53 in human cancer. J Pathol. 223:116–126. 2011.
View Article : Google Scholar
|
|
4
|
Muller PA, Vousden KH and Norman JC: p53
and its mutants in tumor cell migration and invasion. J Cell Biol.
192:209–218. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Navone NM, Labate ME, Troncoso P, Pisters
LL, Conti CJ, von Eschenbach AC and Logothetis CJ: p53 mutations in
prostate cancer bone metastases suggest that selected p53 mutants
in the primary site define foci with metastatic potential. J Urol.
161:304–308. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang SP, Wang WL, Chang YL, et al: p53
controls cancer cell invasion by inducing the MDM2-mediated
degradation of Slug. Nat Cell Biol. 11:694–704. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Boominathan L: The guardians of the genome
(p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs
network. Cancer Metastasis Rev. 29:613–639. 2010. View Article : Google Scholar
|
|
8
|
Chang CJ, Chao CH, Xia W, et al: p53
regulates epithelial-mesenchymal transition and stem cell
properties through modulating miRNAs. Nat Cell Biol. 13:317–323.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim NH, Kim HS, Li XY, et al: A
p53/miRNA-34 axis regulates Snail1-dependent cancer cell
epithelial-mesenchymal transition. J Cell Biol. 195:417–433. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim T, Veronese A, Pichiorri F, et al: p53
regulates epithelial-mesenchymal transition through microRNAs
targeting ZEB1 and ZEB2. J Exp Med. 208:875–883. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schubert J and Brabletz T: p53 spreads out
further: suppression of EMT and stemness by activating miR-200c
expression. Cell Res. 21:705–707. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sethi S, Macoska J, Chen W and Sarkar FH:
Molecular signature of epithelial-mesenchymal transition (EMT) in
human prostate cancer bone metastasis. Am J Transl Res. 3:90–99.
2010.PubMed/NCBI
|
|
14
|
Hugo H, Ackland ML, Blick T, Lawrence MG,
Clements JA, Williams ED and Thompson EW: Epithelial-mesenchymal
and mesenchymal-epithelial transitions in carcinoma progression. J
Cell Physiol. 213:374–383. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Visvader JE and Lindeman GJ: Cancer stem
cells in solid tumours: accumulating evidence and unresolved
questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Monteiro J and Fodde R: Cancer stemness
and metastasis: therapeutic consequences and perspectives. Eur J
Cancer. 46:1198–1203. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bracken CP, Gregory PA, Khew-Goodall Y and
Goodall GJ: The role of microRNAs in metastasis and
epithelial-mesenchymal transition. Cell Mol Life Sci. 66:1682–1699.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gregory PA, Bert AG, Paterson EL, et al:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Korpal M, Lee ES, Hu G and Kang Y: The
miR-200 family inhibits epithelial-mesenchymal transition and
cancer cell migration by direct targeting of E-cadherin
transcriptional repressors ZEB1 and ZEB2. J Biol Chem.
283:14910–14914. 2008. View Article : Google Scholar
|
|
21
|
Liu C, Kelnar K, Liu B, et al: The
microRNA miR-34a inhibits prostate cancer stem cells and metastasis
by directly repressing CD44. Nat Med. 17:211–215. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Siemens H, Jackstadt R, Hünten S, Kaller
M, Menssen A, Götz U and Hermeking H: miR-34 and SNAIL form a
double-negative feedback loop to regulate epithelial-mesenchymal
transitions. Cell Cycle. 10:4256–4271. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hatfield S and Ruohola-Baker H: microRNA
and stem cell function. Cell Tissue Res. 331:57–66. 2008.
View Article : Google Scholar
|
|
24
|
Hermeking H: MicroRNAs in the p53 network:
micromanagement of tumour suppression. Nat Rev Cancer. 12:613–626.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Peng X, Guo W, Liu T, et al:
Identification of miRs-143 and -145 that is associated with bone
metastasis of prostate cancer and involved in the regulation of
EMT. PLoS One. 6:e203412011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang S, Guo W, Tang Y, Ren D, Zou X and
Peng X: miR-143 and miR-145 inhibit stem cell characteristics of
PC-3 prostate cancer cells. Oncol Rep. 28:1831–1837.
2012.PubMed/NCBI
|
|
27
|
Sachdeva M, Zhu S, Wu F, et al: p53
represses c-Myc through induction of the tumor suppressor miR-145.
Proc Natl Acad Sci USA. 106:3207–3212. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Suzuki HI, Yamagata K, Sugimoto K, Iwamoto
T, Kato S and Miyazono K: Modulation of microRNA processing by p53.
Nature. 460:529–533. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shi M, Du L, Liu D, et al: Glucocorticoid
regulation of a novel HPV-E6-p53-miR-145 pathway modulates invasion
and therapy resistance of cervical cancer cells. J Pathol.
228:148–157. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Suh SO, Chen Y, Zaman MS, et al:
MicroRNA-145 is regulated by DNA methylation and p53 gene mutation
in prostate cancer. Carcinogenesis. 32:772–778. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schmittgen TD and Livak KJ: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C (T)) method. Methods. 25:402–408. 2011.
|
|
32
|
Pfeiffer MJ and Schalken JA: Stem cell
characteristics in prostate cancer cell lines. Eur Urol.
57:246–254. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bisson I and Prowse DM: WNT signaling
regulates self-renewal and differentiation of prostate cancer cells
with stem cell characteristics. Cell Res. 19:683–697. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu N, Papagiannakopoulos T, Pan G, Thomson
JA and Kosik KS: MicroRNA-145 regulates OCT-4, SOX2, and KLF4 and
represses pluripotency in human embryonic stem cells. Cell.
137:647–658. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Downing S, Bumak C, Nixdorf S, Ow K,
Russell P and Jackson P: Elevated levels of prostate-specific
antigen (PSA) in prostate cancer cells expressing mutant p53 is
associated with tumor metastasis. Mol Carcinog. 38:130–140. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Stapleton AM, Timme TL, Gousse AE, et al:
Primary human prostate cancer cells harboring p53 mutations are
clonally expanded in metastases. Clin Cancer Res. 3:1389–1397.
1997.PubMed/NCBI
|
|
37
|
Kogan-Sakin I, Tabach Y, Buganim Y, et al:
Mutant p53 (R175H) upregulates Twist1 expression and promotes
epithelial-mesenchymal transition in immortalized prostate cells.
Cell Death Differ. 18:271–281. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vinall RL, Chen JQ, Hubbard NE, Sulaimon
SS, Shen MM, Devere White RW and Borowsky AD: Initiation of
prostate cancer in mice by Tp53R270H: evidence for an alternative
molecular progression. Dis Model Mech. 5:914–920. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou Z, Flesken-Nikitin A, Corney DC, Wang
W, Goodrich DW, Roy-Burman P and Nikitin AY: Synergy of p53 and Rb
deficiency in a conditional mouse model for metastatic prostate
cancer. Cancer Res. 66:7889–7898. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhou Z, Flesken-Nikitin A and Nikitin AY:
Prostate cancer associated with p53 and Rb deficiency arises from
the stem/progenitor cell-enriched proximal region of prostatic
ducts. Cancer Res. 67:5683–5690. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Martin P, Liu YN, Pierce R, et al:
Prostate epithelial Pten/TP53 loss leads to transformation of
multipotential progenitors and epithelial to mesenchymal
transition. Am J Pathol. 179:422–435. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dong P, Karaayvaz M, Jia N, et al: Mutant
p53 gain-of-function induces epithelial-mesenchymal transition
through modulation of the miR-130b-ZEB1 axis. Oncogene. Jul
30–2012.(Epub ahead of print). View Article : Google Scholar
|
|
43
|
Gao P, Xing AY, Zhou GY, et al: The
molecular mechanism of microRNA-145 to suppress invasion-metastasis
cascade in gastric cancer. Oncogene. 32:491–501. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mani SA, Guo W, Liao MJ, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kong D, Banerjee S, Ahmad A, Li Y, Wang Z,
Sethi S and Sarkar FH: Epithelial to mesenchymal transition is
mechanistically linked with stem cell signatures in prostate cancer
cells. PLoS One. 5:e124452010. View Article : Google Scholar : PubMed/NCBI
|
